Lilly's halts trials of Zyprexa replacement in schizophrenia
This article was originally published in Scrip
Executive Summary
Eli Lilly ceded defeat in its fight to replace some of the revenue lost to generic competition for its blockbuster Zyprexa (olanzapine) when on 29 August it announced it would end development of the schizophrenia drug candidate pomaglumetad methionil (LY2140023) – an oral glutamate 2 and 3 receptor agonist – after a second pivotal study failure.